The review, led by researchers at the Medical University of Warsaw together with collaborators at the University of Warsaw and Penn State College of Medicine, synthesizes findings from preclinical models, human cohorts and mechanistic studies across the full spectrum of hepatic pathology. Its central message is one of context: the direction in which miR-122 moves, whether up or down, depends critically on which biological compartment is measured and at what stage of disease. Hepatic expression of the microRNA tends to decline as disease progresses, while circulating levels rise with hepatocyte injury. Far from being contradictory, the authors argue, these opposing patterns reflect distinct biological processes and must be interpreted together for miR-122 to serve as a valid biomarker.

Nowhere is this more relevant than in metabolic dysfunction-associated fatty liver disease, or MAFLD, a condition now estimated to affect between twenty-five and thirty percent of the global population. The disease begins as simple steatosis and can progress to inflammatory steatohepatitis, fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma or acute liver failure. In mouse models fed a high-fat diet and in hepatic cells exposed to free fatty acids, miR-122 expression rises, suppressing the metabolic sensor Sirt1 and thereby activating the lipogenic genes SREBP1, FASN, ACC1 and SCD1. Inhibiting miR-122 restores Sirt1, reactivates the downstream LKB1/AMPK energy-sensing pathway and reduces fat accumulation in liver cells, establishing the miR-122/Sirt1 axis as a key driver of hepatic lipogenesis.

Human studies reinforce this mechanistic picture. Early clinical work from 2011 showed that circulating miR-122, together with miR-34a, was substantially elevated in MAFLD patients compared with healthy controls, with levels increasing progressively as simple steatosis gave way to steatohepatitis and correlating with liver enzymes, fibrosis stage and inflammatory markers. In a Japanese cohort of sixty-seven patients in whom paired liver and serum samples were available, hepatic and circulating miR-122 levels tracked each other closely, yet the relationship with fibrosis proved stage-dependent: expression was higher in mild than in severe fibrosis. A separate longitudinal biopsy study found that changes in circulating miR-122 were linked to steatosis, ballooning degeneration and fibrosis over a median follow-up of 4.6 years. More recently, a 2025 systematic review of 1,149 studies identified miR-122 as the most frequently investigated circulating microRNA in MASLD, appearing in roughly thirty-six percent of studies and reaching diagnostic AUROCs of 0.81 to 1.0 for steatohepatitis.

The inflammatory dimension of the story connects the gut to the liver. In an Egyptian study of fifty MAFLD patients, fifty MASH patients and fifty healthy controls, blood-exosomal miR-122 and miR-128 were upregulated alongside the bacterial product LPS, its receptor TLR-4 and the transcription factor FoxO3, while adiponectin and several other microRNAs were downregulated. This LPS/TLR-4/FoxO3 signaling axis links gut microbial imbalance to hepatic inflammation and offers a mechanistic route by which miR-122 participates in the transition from fatty liver to inflammatory disease. Adipocyte-derived exosomes add another layer: these vesicles carry high levels of miR-122 into hepatocytes, where suppression of Sirt1 increases gluconeogenic and lipogenic enzymes, raises inflammatory cytokines such as TNF-alpha and IL-1beta, and reduces fat oxidation through PPARalpha.

In acute liver injury, miR-122 behaves as a sensitive gauge of hepatocyte damage. In acetaminophen-induced injury models, the drug increased liver necrosis, inflammation, serum transaminases and miR-122-5p expression, while a miR-122-5p suppressor partially reversed these effects through upregulation of the target gene NDRG3 and favorable shifts in apoptotic markers, increasing Bcl-w and Bcl-2 while decreasing Bax. In a clinical cohort of 223 critically ill patients, serum miR-122 was substantially elevated compared with healthy controls, correlated strongly with traditional injury markers including ALT, AST and GLDH, and persisted as an independent indicator of hepatocyte injury regardless of whether the underlying condition was septic or non-septic.

Viral hepatitis reveals the molecule’s most striking paradox. In hepatitis B virus infection, miR-122 acts as a natural antiviral factor: overexpression in hepatoma cells suppressed HBsAg, HBeAg and viral DNA by fifty to seventy percent, while inhibition doubled HBV mRNA levels. Clinically, serum miR-122 was lower in HBV patients than in controls and inversely correlated with viral load. Mechanistically, miR-122 downregulates cyclin G1, disrupting its interaction with p53 and thereby removing a pro-viral loop; it also induces the antiviral enzyme heme oxygenase-1. In hepatitis C, by contrast, miR-122 is essential for viral replication, binding the HCV genome and stabilizing it. Circulating miR-122 is nonetheless elevated in chronic HCV patients, correlates with disease severity independently of viral load, and its upregulation appears independent of viral genotype, holding across both genotype 1 and genotype 3 predominant populations.

In hepatocellular carcinoma, loss of miR-122 emerges as a key oncogenic event. Tumor tissue from 142 HBV-related liver cancers showed significantly reduced miR-122, and low expression correlated with larger tumors, venous invasion, poor differentiation and reduced overall survival. Multiple target axes explain the tumor-suppressive effect: derepression of NDRG3, PTTG1-binding factor, PEG10 and GALNT10 each contributes to tumor growth, invasion and progression, while the Hnf4alpha/miR-122/GALNT10 pathway links transcriptional dysregulation to oncogenic protein activity. Mice engineered to lack miR-122 develop dysregulated lipid metabolism, steatosis, fibrosis and spontaneous liver cancer with epithelial-mesenchymal features; reintroducing the microRNA reverses these defects. Notably, the regulation of miR-122 differs by etiology: in HBV-associated HCC, epigenetic silencing through a PPARgamma/RXRalpha complex, histone methylation by SUV39H1 and viral protein effects drive suppression, whereas in chronic HCV the reduction appears linked to the host interferon response.

The therapeutic history of anti-miR-122 drugs is a cautionary tale. Miravirsen, a locked nucleic acid-modified antisense oligonucleotide and the first anti-microRNA drug to enter human trials, produced dose-dependent and sustained reductions in HCV RNA in phase 2a studies. Yet development was discontinued after viral resistance emerged through mutations in the viral 5-prime untranslated region that permitted miR-122-independent replication, and after direct-acting antivirals achieved cure rates above ninety-five percent, rendering a host-targeted strategy largely redundant. The GalNAc-conjugated antagomir RG-101 achieved marked viral-load reductions, including sustained virological responses after a single dose, but was placed on FDA clinical hold in 2016 following cases of severe hyperbilirubinemia attributed to inhibition of the MRP2 bilirubin transporter combined with preferential uptake into hepatocytes. Beyond these specific liabilities lies a more fundamental concern: because miR-122 is a tumor suppressor whose loss drives steatosis, fibrosis and cancer, sustained systemic suppression carries a theoretical long-term oncogenic risk.

The review’s authors conclude that the future of miR-122 lies in restoration rather than inhibition, particularly for metabolic and neoplastic liver disease, and in its use as a minimally invasive biomarker within multi-marker panels rather than as a standalone diagnostic. Given its high sensitivity to hepatocellular injury but limited disease specificity, serial measurement of circulating miR-122, ideally alongside other microRNAs and conventional markers, is likely to outperform any single-timepoint reading. A longitudinal study of eighty-one Japanese MAFLD patients illustrates the prognostic potential: among patients with persistent severe fibrosis, those who later developed liver cancer had significantly lower miR-122 levels, and a miR-122 ratio below 0.5 predicted higher cancer incidence and poorer survival. Standardized assays, longitudinal multi-omics studies and well-designed trials of miR-122-restoring strategies, the authors argue, are the necessary next steps to translate two decades of mechanistic insight into clinical benefit for the hundreds of millions of people living with liver disease worldwide.

Subject of Research: The role of microRNA-122 as a regulator and biomarker of liver disease

Article Title: MicroRNA-122 as a regulator and biomarker of liver disease

Article References: Ahmadova, S., Wicik, Z., Mucha, J., Palatini, J., Ziętal, K., Mirowska-Guzel, D., Przybylkowski, A., & Eyileten, C. (2026). MicroRNA-122 as a regulator and biomarker of liver disease. Journal of Molecular Medicine, 104(1), Article 110. https://doi.org/10.1007/s00109-026-02718-1

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02718-1

Keywords: microRNA-122, liver disease, MAFLD, MASH, hepatitis B, hepatitis C, hepatocellular carcinoma, biomarker, fibrosis, lipid metabolism, antiviral therapy, miravirsen

Hepatic steatosis, commonly referred to as fatty liver, is a hallmark of metabolic syndrome and often precedes more severe liver conditions such as steatohepatitis, fibrosis, and cirrhosis. The condition is characterized by the abnormal accumulation of triglycerides within hepatocytes, which can trigger local inflammation and cellular stress leading to liver damage. Despite decades of research, the precise molecular communications between adipose tissue and the liver that exacerbate this lipid dysregulation remain underexplored. This new study has focused on extracellular vesicles as vehicles of molecular messages between tissues, deciphering how adipocyte-secreted sEVs influence hepatic lipid homeostasis.

Extracellular vesicles, particularly small exosomes ranging from 30 to 150 nanometers, are released by virtually all cell types and serve as carriers of nucleic acids, proteins, and lipids. These vesicles are now recognized as crucial mediators of intercellular signaling. In adipocytes, sEVs encapsulate a spectrum of miRNAs, which upon delivery to target cells, regulate gene expression programs essential for maintaining metabolic balance. The researchers identified that miR-30a-3p is abundantly packaged into adipocyte-derived sEVs in mice fed a high-fat diet, suggesting diet-induced changes in vesicle cargo.

To unravel the impact of miR-30a-3p on the liver, the team employed sophisticated in vivo tracing techniques, confirming that adipocyte-derived sEVs can cross tissue barriers and are taken up by hepatocytes. Once inside liver cells, miR-30a-3p exerts profound effects by downregulating key metabolic regulators involved in lipid catabolism. Notably, the microRNA targets genes that facilitate fatty acid oxidation and mitochondrial function, thereby promoting lipid accumulation within hepatocytes. These molecular cascades illustrate how a single miRNA species delivered via extracellular vesicles can orchestrate complex metabolic derangements.

High-fat diets are known to alter adipocyte function, including changes in vesicle secretion dynamics and cargo composition. The study demonstrated that diet-induced obesity leads to an upregulation of miR-30a-3p expression in adipose tissue, which translates into higher levels of this microRNA in circulating sEVs. This establishes a direct mechanistic link between nutritional excess and molecular communication pathways that disturb liver metabolism. These findings point toward the systemic nature of metabolic diseases, emphasizing the need to consider inter-organ communication when designing interventions.

Intriguingly, the researchers also employed genetic knockdown approaches to silence miR-30a-3p in adipocytes, which resulted in a marked reduction in hepatic steatosis severity in high-fat diet-fed mice. This highlights the potential of therapeutic strategies that target the biogenesis or loading of sEVs, or specifically inhibit problematic miRNAs, as novel treatments for fatty liver disease. Given the challenge of delivering nucleic acid therapeutics efficiently to specific tissue compartments, extracellular vesicles themselves might be engineered as delivery vehicles, opening cutting-edge pathways in nanomedicine.

The work further explored downstream targets of miR-30a-3p within hepatocytes to decode the transcriptional network affected by this microRNA. The repression of PPARα (peroxisome proliferator-activated receptor alpha), a master regulator of lipid oxidation pathways, was particularly notable. Loss of PPARα activity diminishes the liver’s capacity to break down fats, favoring the accumulation of triglycerides. Additionally, miR-30a-3p influenced mitochondrial biogenesis factors, suggesting a broad impairment of hepatocellular energy metabolism. These data collectively underscore the central role of miR-30a-3p in rewiring hepatic metabolic pathways via post-transcriptional regulation.

Importantly, the study design accounted for sex-specific effects by focusing on male mice, given the known differences in fat distribution and metabolism between sexes. This approach acknowledges the complexity of metabolic disease phenotypes and the necessity to explore how extracellular vesicle-mediated mechanisms may vary by sex. Future research expanding these observations to female models and other metabolic contexts could provide a more comprehensive understanding of miRNA roles under various physiological conditions.

Beyond the molecular insights, the translational implications of this research are significant. Non-alcoholic fatty liver disease (NAFLD) affects millions worldwide and currently lacks targeted pharmacological treatments. Understanding how adipocyte-derived extracellular vesicles contribute to disease progression offers fresh biomarkers for early detection and monitoring of NAFLD. Moreover, circulating miR-30a-3p levels in plasma sEVs could serve as minimally invasive indicators of liver health or metabolic state in patients.

The study’s integrated methodology combined lipidomics, transcriptomics, and functional assays, providing a multifaceted view of the interplay between adipose tissue and the liver. Advanced imaging techniques confirmed vesicle trafficking routes, while RNA sequencing identified gene networks disrupted by miR-30a-3p. This systems biology approach sets a new standard for studying inter-tissue communication in complex metabolic diseases and establishes a framework for investigating other vesicle-associated miRNAs in varied pathologies.

As obesity rates continue to rise globally, unraveling the mechanisms that link disrupted adipocyte function to downstream organ damage is vital. This study redefines the role of adipose tissue beyond fat storage as an active endocrine organ that exploits extracellular vesicles to influence distant tissues negatively. Targeting the molecular conversations mediated by extracellular vesicles represents a paradigm shift in the treatment of metabolic syndrome-associated complications such as hepatic steatosis.

In conclusion, Zhang and colleagues have masterfully demonstrated that small extracellular vesicles secreted by adipocytes are not merely byproducts but active vehicles of pathological signals. The delivery of miR-30a-3p to hepatocytes disrupts critical metabolic pathways, driving the progression of fatty liver disease in high-fat diet contexts. This discovery opens exciting possibilities to modulate extracellular vesicle content and communication patterns as therapies for human metabolic disorders.

As researchers continue to dissect the vesicle-mediated miRNA networks in various tissues, the current findings spotlight the complexity and precision of intercellular signaling in health and disease. The future of metabolic medicine may hinge on decoding and manipulating these nanoscale messages, offering hope for millions suffering from obesity-related liver diseases and beyond.

Subject of Research:
The role of adipocyte-derived small extracellular vesicle microRNA-30a-3p in exacerbating hepatic steatosis in male mice subjected to a high-fat diet.

Article Title:
Adipocyte small extracellular vesicle-derived microRNA-30a-3p exacerbates hepatic steatosis in high fat diet-fed male mice.

Article References:
Zhang, T., Hu, L., Chen, D. et al. Adipocyte small extracellular vesicle-derived microRNA-30a-3p exacerbates hepatic steatosis in high fat diet-fed male mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71731-2

Image Credits: AI Generated